Elepsia Xr 1000 Mg Tablet, Extended Release
Product Images NDC 80705-100

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Elepsia Xr 1000 Mg (NDC 80705-100). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Tripoint Therapeutics, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Elepsia 01)

Chemical structure of levetiracetam, the active ingredient in ELEPSIA XR 1500 MG extended-release tablets by TRIPOINT THERAPEUTICS, LLC. The structure depicts a pyrrolidone ring with ethyl and amide substituents.*

FDA Label Image

Figure 1 (Elepsia 02)

A bar chart displaying the percentage of patients across three groups: Placebo (7.4%), Immediate-release Levetiracetam 1,000 mg/day (37.1%), and Immediate-release Levetiracetam 3,000 mg/day (39.6%). The vertical axis shows the percent of patients, and each bar is labeled with the respective number of patients (N) per group.*

FDA Label Image

Figure 2 (Elepsia 03)

A bar chart depicting the percentage of patients across three groups: Placebo (6.3%, N=111), Immediate-release Levetiracetam 1,000 mg/day (20.8%, N=106), and Immediate-release Levetiracetam 2,000 mg/day (35.2%, N=105). The y-axis represents the percentage of patients, ranging from 0% to 45%, with corresponding values indicated above each bar.*

FDA Label Image

Figure 3 (Elepsia 04)

A bar chart comparing the percentage of patients between two groups: Placebo (N=104) with 14.4% and Immediate-release Levetiracetam 3,000 mg/day (N=180) with 39.4%. The y-axis represents the percentage of patients from 0% to 45%.*

FDA Label Image

Figure 4 (Elepsia 05)

A bar chart comparing the percentage of patients between two groups: Placebo (N=97) at 19.6% and Immediate-release Levetiracetam (N=101) at 44.6%. The y-axis represents the percentage of patients, ranging from 0% to 45%. An asterisk marks the bar for Immediate-release Levetiracetam.*

FDA Label Image

Principal Display Panel (1000 mg Tablet Bottle Label)

ELEPSIA XR 1000 mg extended-release tablets label for levetiracetam, manufactured by Sun Pharmaceutical Industries Ltd. and labeled by Tripoint Therapeutics, LLC. The label includes dosing instructions for once daily use, storage conditions, a barcode, and packaging information for a 30-tablet container. The label emphasizes swallowing tablets whole without chewing or crushing.*

FDA Label Image

Principal Display Panel (1500 mg Tablet Bottle Label)

Label for ELEPSIA XR 1500 mg (levetiracetam) extended-release tablets. This oral prescription drug by Tripoint Therapeutics, LLC is presented in a 30-tablet package. The label includes dosage instructions, storage guidelines, and manufacturer information (Sun Pharmaceutical Industries Ltd., India). It also features the Tripoint Therapeutics logo and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.